Economy/Home · Economy

Hanmi Pharm Signs 3.1892 Trillion Won Tech Transfer Deal with Genentech... Stock Soars 15%, VI Triggered

Hanmi Pharmaceutical (128940) saw its stock surge from the opening bell, triggering the volatility curb (VI), after news that it signed a technology transfer contract worth a total of 2.305 billion dollars (approx. 3.1892 trillion won) with U.S.-based Genentech. **15.88% Surge Amid KOSPI Weakness..

Oseong Kwon
Staff Reporter
8 min read
Hanmi Pharm Signs 3.1892 Trillion Won Tech Transfer Deal with Genentech... Stock Soars 15%, VI Triggered
CBC News

Hanmi Pharmaceutical (128940) saw its stock surge from the opening bell, triggering the volatility curb (VI), after news that it signed a technology transfer contract worth a total of 2.305 billion dollars (approx. 3.1892 trillion won) with U.S.-based Genentech.

15.88% Surge Amid KOSPI Weakness... VI Triggered During Session

On the 24th, a static VI was triggered for Hanmi Pharmaceutical at 11:16:16 a.m. Earlier, at 11:15:20 a.m., a dynamic VI was triggered on NexTrade (NXT).

As of 11:18 a.m., Hanmi Pharmaceutical was trading at 481,500 won, up 66,000 won (15.88%) from the previous close. With buying pressure flooding in from the open, the stock climbed to the 480,000-won level in one fell swoop. As the intraday volatility expanded enough to trigger the VI, attention is focused on whether the stock can extend its gains for the remainder of the session.

The domestic stock market showed mixed movements today. At the same time, the KOSPI was down 154.31 points (2.23%) at 6,758.64, while the KOSDAQ was up 12.23 points (1.52%) at 814.17. Even as the KOSPI fell more than 2%, Hanmi Pharmaceutical jumped over 15%, showing a standout performance. However, stocks that surge intraday can see heightened volatility depending on shifts in supply and demand, so the trend should be watched until the close.

Background of the Surge: A 3-Trillion-Won-Scale Technology Transfer Deal

Behind the stock's surge lies a large-scale technology transfer deal. Hanmi Pharmaceutical announced it signed a technology transfer contract with U.S.-based Genentech, Inc. worth a total of 2.305 billion dollars (approx. 3.1892 trillion won) for HM17321 (LA-UCN2). The deal concerns 'HM17321,' a long-acting UCN2 analogue that selectively activates the CRF2 receptor.

During the contract period, Hanmi Pharmaceutical grants Genentech an exclusive license for research, development, manufacturing, and commercialization. The contract territory covers the entire world excluding South Korea, and the contract period runs until the expiration date of the royalty term.

262.9 Billion Won Upfront, 2.9263 Trillion Won in Milestones... No Obligation to Return

The total contract amount is 2.305 billion dollars, which comes to approximately 3.1892 trillion won when applying the initial exchange base rate of 1,383.60 won per dollar as of August 24, 2026. Of this, the upfront payment is 190 million dollars (approx. 262.9 billion won) and milestones amount to 2.115 billion dollars (approx. 2.9263 trillion won).

The milestone payments are to be received in stages based on clinical development, approval, and commercialization, and Hanmi Pharmaceutical will also receive royalties based on annual net sales after market launch. Details of the milestones and royalties were not disclosed.

The contract takes effect once administrative procedures, such as the U.S. Hart-Scott-Rodino Antitrust Improvements Act (HSR Act), are satisfied. According to the regulatory filing, the contract may be terminated if clinical trials, approval, or commercialization are not realized, but Hanmi Pharmaceutical has no obligation to pay penalties upon termination. There is no obligation to return the upfront payment or milestones, and the milestones are receivable upon achieving the relevant conditions.

Revenue Recognition May Vary Depending on Clinical and Approval Success

Hanmi Pharmaceutical stated that revenue recognition from this technology transfer contract may vary depending on the success of clinical trials and product approval. It explained that the contract could be terminated if research and development is halted by regulatory authorities or if product approval fails.

[※ This article is for informational purposes regarding investment and does not recommend investment in, or the purchase or sale of, any specific stock.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.